
February 20th (Sunday) Hana

15:35~16:35 Poster Session Therapeutic advances in gout and hyperuricemia

- P-006 Effects of bovine milk ingestion on urinary excretion of oxypurinol and uric acid**
Masafumi Kurajoh / Tuneyoshi Ka / Chihiro Okuda / Asako Yamamoto / Zenta Tsutsumi / Hidenori Koyama / Yuji Moriwaki / Tetsuya Yamamoto
(Department of Internal Medicine, Hyogo College of Medicine)
- P-007 Clinical efficacy and safety of topiroxostat (FYX-051) in subjects with hyperuricemia and gout**
Iwao Ohno¹⁾ / Tetsuya Yamamoto²⁾ / Takanori Ueda³⁾ / Shin Fujimori⁴⁾ / Tatsuo Hosoya¹⁾
(Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine¹⁾, Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine²⁾, First Department of Internal Medicine, Faculty of Medical Science, University of Fukui³⁾, Department of Internal Medicine, Teikyo University School of Medicine⁴⁾)
- P-008 Effect of change in urine pH by manipulating food materials on urinary uric acid excretion**
Issei Seyama / Aya Kanbara
(Department of Nutrition and Health Promotion, Faculty for Human Development, Hiroshima Jyogakuin University)
- P-009 Febuxostat (vs. Allopurinol) in Treating the Hyperuricemia of Gout Patients ≥ 65 Years of Age (≥ 65 y)tak**
Michael Becker¹⁾ / Patricia A. MacDonald²⁾ / Barbara Hunt²⁾ / Lhanoo Gunawardhana²⁾
(University of Chicago¹⁾, Takeda Global Research and Development²⁾)
- P-010 Effect of xanthine oxidoreductase inhibitors on the ALS transgenic mouse model**
Teruo Kusano¹⁾ / Ken Okamoto¹⁾ / Takeshi Nishino^{1,2)} / Masako Kato³⁾ / Sinsuke Kato⁴⁾
(Department of Biochemistry and Molecular Biology, Nippon Medical School¹⁾, Department of Biochemistry, University of California, Riverside²⁾, Division of Molecular Pathology, Department of Microbiology and Pathology, Tottori University Faculty of Medicine³⁾, Division of Neuropathology, Department of Brain and Neurosciences, Tottori University Faculty of Medicine⁴⁾)

15:35~16:35 Poster Session Transport of Purine/Pyrimidine

- P-011 The increased protein level of Urat1 was observed in obesity/metabolic syndrome model mice**
Makoto Hosoyamada / Sumire Asanuma / Yuichi Takiue / Masaki Kimura / Hidetsugu Saito
(Div. of Pharmacotherapeutics, Keio University Faculty of Pharmacy)

-
- P-012 Elucidation of urate transport mechanism by analysis of renal urate transporters' transgenic mice**
Toru Kimura¹⁾ / Ai Tsukada²⁾ / Sirirat Amonpatumrat¹⁾ / Toshiyuki Fukutomi¹⁾ / Promsuk Jutabha¹⁾ / Thanapol Thammaprafip¹⁾ / Eun Ji Lee¹⁾ / Kimiyoshi Ichida²⁾ / Naohiko Anzai¹⁾ / Hiroyuki Sakurai¹⁾
(Department of Pharmacology and Toxicology, Kyorin University School of Medicine¹⁾, Department of Pathophysiology, Tokyo University of Pharmacy and Life Science²⁾)
- P-013 The effect of sex hormones upon urate transport systems in the mouse kidney**
Yuichi Takiue / Makoto Hosoyamada / Masaki Kimura / Hidetsugu Saito
(Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy)
- P-014 Clarification of uric acid metabolic mechanism in pregnancy**
Ichiro Uehara¹⁾ / Toru Kimura²⁾ / Shinji Tanigaki¹⁾ / Mitsutoshi Iwashita¹⁾ / Naohiko Anzai²⁾ / Hiroyuki Sakurai²⁾
(Kyorin University School of Medicine, Obstetrics and Gynecology¹⁾, Kyorin University School of Medicine, Pharmacology²⁾)
- P-015 Identification of PDZ domain proteins as binding partners of a novel voltage-driven organic anion transporter NPT4 (*SLC17A3*) in the kidneys**
T Fukutomi / N Anzai / P Jutabha / H Sakurai / H Endou
(Dept. of Pharmacology and Toxicology, Kyorin University School of Medicine. Tokyo, Japan)

15:35~16:35 Poster Session Purine/Pyrimidine in malignancies

- P-024 Hyperuricemia in pediatric malignancies before treatment**
Ayako Nagai¹⁾ / Masaru Kubota¹⁾ / Li Tang¹⁾ / Souichi Adachi²⁾ / Ikuya Usami³⁾ / Kousaku Matsubara⁴⁾
(Faculty of Human Life and Environment, Nara Women's University¹⁾, Department of Pediatrics, Kyoto University²⁾, Department of Pediatrics, Kobe City General Hospital³⁾, Department of Pediatrics, Nishi-Kobe Medical Center⁴⁾)
- P-025 Pharmacogenetics of 5-Fluorouracil and Capecitabine Therapy**
Anthony Marinaki¹⁾ / Aathavan Loganayagam²⁾ / Monica Arenas Hernandez¹⁾ / Cathryn Lewis⁴⁾ / Paul Ross³⁾ / Jeremy Sanderson²⁾
(Purine Research Laboratory, GSTS Pathology, Guy's and St Thomas' Hospitals¹⁾, Gastroenterology, Guy's and St Thomas' Hospitals²⁾, Oncology, Guy's and St Thomas' Hospitals³⁾, Medical and Molecular Genetics, Kings College London⁴⁾)
- P-026 The Immuno-TK ELISA as a tumour marker for lymphoma and leukemia patients**
Ruby Cooray^{1,2)} / Per Venge²⁾ / Rolf Larsson¹⁾ / Daniel Molin³⁾ / Staffan Eriksson^{4,5)}
(Dept of Medical Sciences, Uppsala University¹⁾, Diagnostics Development, Uppsala²⁾, Dept of Oncology, Radiology, and Clinical Immunology Uppsala University³⁾, Dept Anatomy Physiology and Biochemistry, The Swedish University of Agricultural Sciences, Uppsala⁴⁾, AroCell AB, Uppsala⁵⁾)

-
- P-027 Overcoming ara-C resistance in HL-60 cells using 9-β-D-arabinofuranosylguanine and Bcl-2 inhibitor YC137**
Rie Nishi / Takahiro Yamauchi / Eiju Negoro / Takanori Ueda
(Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui)
- P-028 Digalloylresveratrol inhibits ribonucleotide reductase in human leukemia and pancreatic cancer cells**
Philipp Saiko¹⁾ / Geraldine Graser¹⁾ / Sibylle Madlener²⁾ / Andreas Lackner³⁾ / Michael Grusch³⁾ / Georg Krupitza²⁾ / Walter Jaeger⁴⁾ / Trimurtulu Golakoti⁵⁾ / Monika Fritzer-Szekeres¹⁾ / Thomas Szekeres¹⁾
(Department of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria¹⁾, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria²⁾, Department of Medicine I, Division of Cancer Research, Medical University of Vienna, Vienna, Austria³⁾, Department of Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Vienna, Austria⁴⁾, Laila Impex R&D Center Unit I, Vijayawada, Andhra Pradesh, India⁵⁾)
- P-029 Thymidine protection of rapamycin cytotoxicity by increased p70/S6k phosphorylation and autophagy**
Irene V Bijnsdorp¹⁾ / Frank A Kruijt²⁾ / Masakazu Fukushima³⁾ / Godefridus J Peters¹⁾
(VU University Medical Center¹⁾, University Medical Center Groningen²⁾, Taiho Pharmaceuticals³⁾)
- P-030 Cytotoxicity and mechanism of action of difluorodeoxyuridine; the primary catabolite of Gemcitabine**
Richard J Honeywell / Veronique W Ruiz van Haperen / Elisa Giovannetti / Kees Smid / Godefridus J Peters
(VU University Medical Center)

15:35~16:35 Poster Session Miscellaneous

- P-038 Stable isotope dilution mass spectrometric assay for PRPP using enzymatic procedures**
Yoshihiko Shinohara / Yuta Suzuki / Hiroshi Hasegawa / Makiko Nakamura / Kimiyoshi Ichida
(Tokyo University of Pharmacy and Life Sciences)
- P-039 Characterization of the URC pyrimidine degradation pathway**
Anna Rasmussen / Klaus Schnackerz / Halfdan Beck / Olof Bjornberg / Mingming Lai / You Lv / Stacy Keller / Jure Piškur
(Department of Biology, Lund University)

-
- P-040 Instrumental analysis of the urinary stone from the patient with hyperuricemia**
Kiyoko Kaneko¹⁾ / Norifumi Yoshida¹⁾ / Keitaro Okazaki¹⁾ / Tomoyo Yamanobe²⁾ / Hiroka Hachisu¹⁾ / Noriko Yamaoka¹⁾ / Makoto Yasuda¹⁾ / Nobuyuki Ogata³⁾ / Yasukazu Yamada⁴⁾ / Shunya Uchida³⁾ / Shin Fujimori³⁾
(Dept. of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Teikyo University¹⁾, Central Laboratory of Analytical Biochemistry, Teikyo University²⁾, Dept. of Internal Medicine, Faculty of Medicine, Teikyo University³⁾, Department of Genetics, Institute for Developmental Research, Aichi Human Service Center⁴⁾)
- P-041 Developing potent URAT inhibitors**
Bettina Quade¹⁾ / Morin Frick¹⁾ / Promsuk Jutabha²⁾ / Hitoshi Endou²⁾ / Peter Rice¹⁾ / Michael Wempe¹⁾
(University of Colorado Denver¹⁾, Kyorin University School of Medicine²⁾)
- P-042 A growth inhibitory peptide sequence with enhanced effect in bacteria with nucleotide disbalance**
Marianne Lauridsen / Louise Slot Christensen / Birgitte Munch-Petersen
(Roskilde University, Dept Science, Systems and Models)
- P-043 Multi-Dimensional Separations in Clinical Analysis**
D. Perrett¹⁾ / S.P. Dixon¹⁾ / I.D. Pitfield²⁾
(Bioanalytical Science, WHRI, Barts & The London, Queen Mary's School of Medicine & Dentistry, Charterhouse Square, London¹⁾, GlaxoSmithKline plc, Old Powder Mills, nr. Leigh, Tonbridge, Kent²⁾)
- P-044 Rapid method to measure thioguanine incorporation into DNA**
S Vikingsson¹⁾ / B Carlsson¹⁾ / SA Coulthard²⁾ / M Josefsson³⁾ / S Almer⁴⁾ / C Peterson¹⁾
(Division of Drug Research, Clinical Pharmacology, Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden¹⁾, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK²⁾, Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden³⁾, Division of Gastroenterology and Hepatology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden⁴⁾)
- P-045 Thymidine Kinase 1 is an ATP Dependent Tetramer in Vertebrates**
Zeeshan Mutahir¹⁾ / Karl-Magnus Andersson¹⁾ / Birgitte Munch-Peteresen²⁾ / Jure Piskur¹⁾
(Department of Biology, Lund University, Lund¹⁾, Department of Science, Systems and Models, Roskilde University, Roskilde²⁾)

15:35~16:35 Poster Session Purine/Pyrimidine as antimicrobials including anti-viral agents

- P-058 Metabolism of deoxypyrimidines and deoxypyrimidine antiviral analogs in isolated brain mitochondria**
Kathleen A. McCann / David Williams / Edward E. McKee
(Indiana University School of Medicine)

-
- P-059 Maintenance and transport of mitochondrial deoxynucleotide triphosphate pools in heart mitochondria**
Edward E. McKee^{1,2,3} / Christopher Thomas¹ / Kevin McAbee¹ / Laura Verwilst² / Timothy Thayer² / Peter Chhoy²
(Indiana Univ. School of Medicine-South Bend¹, Dept. Biological Sci., Univ. Notre Dame², Eck Institute for Global Health³)

15:35~16:35 Poster Session Purine/Pyrimidine in cell cycle regulation, epigenetics and signal transduction

- P-060 Mitochondrial dysfunction, dNTP levels and mutagenesis**
Claus Desler / Lene Juel Rasmussen
(Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen)
- P-061 Studies of p53R2 expression level after different doses of irradiation in human lung fibroblast MRC-5 cells**
Farideh Habibi / Reza Rofougaran / Bahram Goliaei
(Institute of Biochemistry and Biophysics, Tehran University, Tehran, Iran)

15:35~16:35 Poster Session Purine/Pyrimidine enzyme regulation

- P-068 Canceled**
- P-069 Region- & cell-specific gene expression analysis of the enzymes required for de novo pyrimidine synthesis in the CNS**
Johannes Gerlach¹ / Monika J. Löffler¹ / Martin K. Schafer²
(Institute of Physiological Chemistry, University of Marburg¹, Institute of Anatomy and Cell Biology, University of Marburg²)
- P-070 Simultaneous determination of purine and pyrimidine metabolites in HPRT-deficient cell lines**
Noriko Yamaoka¹ / Katsunori Inazawa¹ / Satoko Inagawa¹ / Shin Fujimori² / Makoto Yasuda¹ / Ken-ichi Mawatari¹ / Kazuya Nakagomi¹ / Yasukazu Yamada³ / Kiyoko Kaneko¹
(Dept. of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Teikyo University¹, Dept. of Internal Medicine, Faculty of Medicine, Teikyo University², Dept. of Genetics, Institute for Developmental Research, Aichi Human Service Center³)
- P-071 Studies of consequence of dNTP pools imbalance on the allosteric regulation of ribonucleotide reductase**
Somayeh Sadat Mirlohi / Reza Rofougaran
(Department of Biochemistry, Institute of Biochemistry and Biophysics, Tehran University, Tehran, Iran)

-
- P-072 Mitochondrial TK2 is a monomer in the absence and presence of its substrates**
Birgitte Munch-Petersen¹ / Tomas Radivoyevitch² / Liya Wang³ / Staffan Eriksson³
(Roskilde University, Dept Science, Systems and Models.¹, Department of Epidemiology and
Biostatistics, Case Western Reserve University, Cleveland, Ohio, U.S.A.², Department of
Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, BMC,
Uppsala, Sweden³)
- P-073 A fluoro at the C-3 position of the CTP synthetase inhibitor 3-deazauridine results in efficient
OPRT inhibition**
Jan Balzarini¹ / Hong Yang² / Karl Miranda³ / Matt A. Peterson⁴ / Morris J. Robins⁴
(Rega Institute for Medical Research¹, Gilead Sciences², Novartis Institute for Biomedical
Research³, Brigham Young University⁴)
- P-074 An unknown path of NAD metabolism that could attenuate SIRT6 activity**
Ewa Slominska / Pawel Romaszko / Ryszard T. Smolenski
(Department of Biochemistry Medical University of Gdansk)
- P-075 METABOLISM OF 4-PYRIDONE-3-CARBOXAMIDE RIBOSIDE**
Ewa Slominska¹ / Pawel Romaszko¹ / Magdalena Abramowicz² / Czeslawa Orlewska³ /
Ryszard T. Smolenski¹
(Department of Biochemistry Medical University of Gdansk¹, Department of Pharmaceutical
Biochemistry Medical University of Gdansk², Department of Organic Chemistry Medical
University of Gdansk³)
- P-076 Effects of 4PYR and its nucleotide derivatives on enzymes of purine and nicotinamide
metabolism**
Ewa Slominska¹ / Iwona Rybakowska² / Ryszard T. Smolenski¹
(Department of Biochemistry Medical University of Gdansk¹, Department of Clinical
Biochemistry and Physiology, Medical University of Gdansk²)
- P-077 Face to face with cN-II**
MG Tozzi¹ / DN Filoni¹ / R Pesi¹ / MG Careddu¹ / M Camici¹ / S Allegrini² / A Collavoli³ /
A Galli³
(Dipartimento di Biologia, Università di Pisa, Italia¹, Dipartimento di Scienze del Farmaco,
Università di Sassari, Italia², Istituto di Fisiologia Clinica, CNR, Pisa, Italia³)